Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study

2012 ◽  
Vol 24 (3) ◽  
pp. 887-897 ◽  
Author(s):  
J. Tamaki ◽  
◽  
M. Iki ◽  
E. Kadowaki ◽  
Y. Sato ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Vertebral Fractures ◽  
Biochemical Markers ◽  
Japanese Population ◽  
Population Based

scholarly journals Effect of age and estrogen on biochemical markers of bone turnover in postmenopausal women: a population-based study from Nepal

2017 ◽  
Vol Volume 9 ◽  
pp. 781-788 ◽  
Author(s):  
Bashu Dev Pardhe ◽  
Sabala Pathak ◽  
Anjeela Bhetwal ◽  
Sumitra Ghimire ◽  
Shreena Shakya ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Biochemical Markers ◽  
Population Based ◽  
Population Based Study ◽  
Markers Of Bone Turnover ◽  
Effect Of Age

Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study

2004 ◽  
Vol 15 (12) ◽  
pp. 981-991 ◽  
Author(s):  
Masayuki Iki ◽  
Takashi Akiba ◽  
Toshio Matsumoto ◽  
Harumi Nishino ◽  
Sadanobu Kagamimori ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Biochemical Markers ◽  
Japanese Population ◽  
Population Based ◽  
Reference Database ◽  
Female Population ◽  
Markers Of Bone Turnover ◽  
Japanese Female

scholarly journals A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women1

2000 ◽  
Vol 85 (6) ◽  
pp. 2197-2202
Author(s):  
Karen M. Prestwood ◽  
Michele Gunness ◽  
Douglas B. Muchmore ◽  
Yili Lu ◽  
Mayme Wong ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Biochemical Markers ◽  
Mineral Density ◽  
Bone Formation Rate ◽  
Markers Of Bone Turnover ◽  
Bone Biopsies ◽  
Hip Bmd ◽  
Total Body

Raloxifene HCl, a selective estrogen receptor modulator, has been shown to increase bone mineral density (BMD) and decrease biochemical markers of bone turnover in postmenopausal women without stimulatory effects on the breast and uterus. However, it is not known whether the changes in BMD and bone turnover are associated with changes at the tissue level, nor how changes with raloxifene compare with estrogen. In this randomized, double blind study, we evaluated the effects of raloxifene (Evista, 60 mg/day) or conjugated equine estrogens (CEE; Premarin, 0.625 mg/day) on bone architecture, bone turnover, and BMD. Iliac crest bone biopsies were obtained at baseline and at the end of the study after double tetracycline labeling and were analyzed for standard histomorphometric indexes. Serum and urinary biochemical markers of bone turnover were measured at baseline and at 4, 10, 18, and 24 weeks of treatment. Total body, lumbar spine, and hip BMD were measured at baseline and at the end of the study by dual energy x-ray absorptiometry. Activation frequency and bone formation rate/bone volume were significantly decreased from baseline in the CEE, but not in the raloxifene, group. Bone mineralization did not change in either group. Most markers of bone resorption and formation decreased in both groups, but to a greater degree in the CEE group (P < .05). Total body and lumbar spine BMD increased from baseline in both groups, with a greater increase in the CEE group (P< 0.05). Hip BMD significantly increased from baseline in the raloxifene group, but the change was not different from that in the CEE group. These results suggest that raloxifene reduces bone turnover and increases bone density, although to a lesser extent than CEE. Thus, raloxifene is an alternative to CEE for the prevention and treatment of osteoporosis in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document